Project Grant R50CA285492
Award Date
8/9/24
Completion Date
7/31/29
Dollars Obligated
$179K
Federal Agency
National Cancer Institute
Awardee
Emory University (S352L5PJLMP8)
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Atlanta, GA 30322, USA
Similar Awards
This $576,659 federal Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research to investigate tumor and host immune signatures associated with disparities in outcomes following GD2 immunotherapy for patients with high-risk neuroblastoma. The primary awardee, Emory University, is collaborating with sub-awardees Dana-Farber Cancer Institute and University of Florida to: Perform tumor-based single cell genomic, proteomic, and...
This $1,108,391.72 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research to define the most therapeutically relevant chimeric antigen receptor (CAR) T cell subsets for treating large B cell lymphoma (LBCL) and overcome immune suppression mechanisms that limit CAR T cell efficacy. The funded project will use a systems biology approach to analyze patient data and pinpoint optimal CAR T cell characteristics for...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $172,013 to support the research work of a pediatric oncologist at the University of Colorado-Denver over the period of September 19, 2024 to August 31, 2029. The funded research aims to improve outcomes for children with acute lymphoblastic leukemia, particularly those who experience disease relapse, through the incorporation of novel targeted therapies into treatment regimens. The...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $249,645 to Boston Children's Hospital to develop advanced genetic engineering techniques to study the role of tumor-specific B cells in cancer progression. The researchers aim to genetically modify B cells to target the HER2 tumor antigen, with the goal of using these engineered B cells as an adoptive immunotherapy to trigger both humoral and cellular anti-tumor immune responses. The...
The National Cancer Institute (NCI) awarded a $1,477,396 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the Beckman Research Institute of the City of Hope in Duarte, CA. The grant, awarded on December 1, 2024, supports a novel approach to enhance the efficacy and durability of CD19 chimeric antigen receptor (CAR) T-cell therapy for B-cell non-Hodgkin's lymphoma (B-NHL). The project involves selecting cytomegalovirus (CMV)-specific T cells, modifying them with a...
This $693,880 Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports the development of a novel cancer immunotherapy approach using engineered CD4+ T cells. The goal is to create CD4+ T cells that can target the tumor microenvironment and overcome resistance to current immune checkpoint inhibitor therapies. Key elements include: Identifying key molecules and immune cell targets of the engineered CD4+ T cells in preclinical cancer...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,283,068 to Washington University to develop and evaluate next-generation radioimmunotherapies for non-Hodgkin lymphoma. The 5-year project aims to create precision radiopharmaceutical therapies using single-agent and combination regimens of B-particle (Lu177) and A-particle (Ac225, Pb212, Th227) emitting anti-CD20 antibodies in preclinical models. It will also assess a...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $108,512 to Emory University to conduct research on the role of the ICOS co-stimulatory molecule in improving the durability and persistence of anti-tumor T cells. The research aims to investigate how ICOS signaling induces resident memory phenotypes in T cells, and how incorporating ICOS into chimeric antigen receptor (CAR) T cells can enhance their anti-tumor efficacy in melanoma....
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) totaling $949,312 provides funding for the University of Florida to develop a "next-generation" precision adoptive cell therapy (ACT) approach for the treatment of pediatric high-grade gliomas. The project aims to utilize patient-specific antigen profiling, a novel gene enrichment strategy, and a selective expansion platform to generate enriched, polyclonal tumor-reactive T...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to harness B cells after stem cell transplant to produce novel chimeric antigen receptor T-cells (CAR-Ts) for treating hematological malignancies. The $415,257 award to Duke University, a leading research institution, will fund research to clone antibody-producing B cells with tumor-binding potential after hematopoietic stem cell transplantation. The goal is to engineer less toxic and...